Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
May 27 2024 - 4:30PM
Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a
clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, today announced that it will report financial results
for the first quarter 2024 ending March 31, 2024 on Tuesday, May
28, 2024 after the close of the US market.
The publication will be followed by an investor
conference call and webcast on Wednesday, May 29, 2024 at 8:00 AM
ET / 2:00 PM CET. The call will include the Company’s first quarter
results and an update on business activities. Details for the call
are as follows:
Dial in information:
Domestic: 1-877-451-6152
International: 1-201-389-0879
Conference ID: 13746795
Webcast Link:
https://viavid.webcasts.com/starthere.jsp?ei=1672725&tp_key=f83e7ab481
About Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with over
24 years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
For further information on Cellectis, please
contact:
Media contact:
Pascalyne Wilson, Director, Communications, +33
(0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the
CEO, +33 (0)7 76 77 46 93
Investor Relations
contacts:
Arthur Stril, Interim Chief Financial Officer,
+1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430
7577
- 20240527_Q1 2024 earnings call announcement_ENGLISH.pdf
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
From Aug 2023 to Aug 2024